Newborn screening for severe combined immunodeficiency (SCID): a review

Area of Science:

• Immunology
• Genetics
• Pediatrics

Background:

• Early diagnosis of inherited metabolic diseases like Severe Combined Immunodeficiency (SCID) is vital for preventing complications.
• Prompt intervention in SCID offers the best chances for successful treatment, especially before severe opportunistic infections occur.
• SCID affects newborns and can be detected via automated blood counts and manual differentials.

Purpose of the Study:

• To highlight the critical need for early diagnosis of Severe Combined Immunodeficiency (SCID) in newborns.
• To propose T-cell lymphopenia (TCLP) testing on dried blood spots (DBS) as a viable screening method for SCID.
• To emphasize the benefits of early SCID detection, including timely treatment and genetic counseling.

Main Methods:

• Review of diagnostic criteria for SCID in newborns.
• Evaluation of automated blood count and manual differential for SCID detection.
• Assessment of T-cell lymphopenia (TCLP) testing on dried blood spots (DBS) for identifying SCID and other immunodeficiencies.

Main Results:

• SCID diagnosis is critical for infants to maximize treatment success.
• Current diagnostic practices for SCID in newborns are infrequent due to its rarity (1 in 50,000 to 100,000 births).
• TCLP testing on DBS offers a potential method for early identification of SCID and other immunodeficiencies.

Conclusions:

• Newborn screening for SCID is essential for early diagnosis and treatment.
• TCLP testing on DBS can facilitate the detection of SCID and other immunodeficiencies in infants.
• Early detection through screening enables prompt medical intervention and genetic counseling for families affected by SCID.